Latest China News

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Renascor Resources has hit key construction milestones at its Australian Government co-funded Purified Spherical Graphite (PSG) demonstration facility, maintaining schedule for on-site commissioning this quarter. The project aims to establish a competitive, HF-free PSG supply chain outside China.

Iondrive Limited has successfully raised $4 million through a share placement to accelerate the commercialisation of its innovative e-waste recycling technology in the United States.

SPC Global Holdings delivered a transformational FY25 with robust financial results and strategic international growth, setting the stage for a confident 25% EBITDA increase in FY26.

Terra Critical Minerals (ASX – T92) has identified notable bismuth mineralisation alongside tungsten, molybdenum, and tin at its Glen Eden Project in NSW, adding a valuable critical mineral to its portfolio amid rising global demand.

BPM Minerals reports outstanding high-grade rare earth element assays from its Durack Project in Western Australia, highlighting the potential for a major monazite-hosted REE deposit. The discovery aligns with growing global demand and Australian government support for critical minerals.

Altech Batteries has secured a strategic collaboration with a leading global battery manufacturer to evaluate its breakthrough Silumina Anodes™ silicon-enhanced technology, marking a significant step toward commercialisation.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Black Bear Minerals has completed the acquisition of the high-grade Shafter Silver Project in Texas, including $150 million in existing infrastructure, positioning itself strategically amid rising silver demand and geopolitical supply shifts.

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.